Ascendis Pharma A/S December 2024 Financial Report: Warrant Exercise Insights

Here are the key insights extracted from the provided section of the financial report (Form 6-K) for Ascendis Pharma A/S:

1. Company Information:

• Name: Ascendis Pharma A/S
• Address: Tuborg Boulevard 12, DK-2900 Hellerup, Denmark
• Commission File Number: 001-36815

2. Report Context:

• This report is filed as a foreign private issuer pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
• The report is for the month of December 2024.

3. Warrant Exercise Window:

• The exercise window for outstanding warrants closed on December 30, 2024.
• During this period, the company registered aggregate share capital increases of nominal DKK 47,343 with the Danish Business Authority.
• This resulted in an increase in the company's total share capital to nominal DKK 60,689,487 through the issuance of 47,343 ordinary shares.
• The average cash consideration received for these shares was approximately USD $66.86 each, based on the exchange rate on the date of the exercise window closure.

4. Capital Structure Changes:

• The issuance of new shares has implications for the company’s capital structure and may dilute existing shareholders unless they participate in the warrant exercises.

5. Document Incorporation:

• This report is deemed to be incorporated by reference into the company’s registration statements on Forms S-8 and F-3, which are related to various registration numbers provided in the document.

6. Signatory:

• The report is signed by Michael Wolff Jensen, Executive Vice President, Chief Legal Officer, confirming the authenticity of the filing on December 30, 2024.

This report provides important updates on the company's capital activities and serves as a formal communication to shareholders and regulators regarding recent changes in share capital and warrant exercises.